Poll

RN Practice Poll #1: Your Strategy After MTX Fails in RA

First in our series of polls about unresolved issues in rheumatology practice: The rheumatoid arthritis patient unhelped by methotrexate monotherapy. What next?

Too many conditions with too many variations. New drug options that arrive too quickly. Too few guidelines to rely on.

On Rheumatology Network, you can help us create an archive of current practice patterns for common conditions not yet addressed by expert consensus or solid evidence-based guidelines. Watch for a new poll every week.

Polls will be updated periodically to monitor changes in practice.

See also:

RN Practice Poll #2:  MTX Plus Anti-TNF Fails in RA: What Next?

 

1. After a patient with rheumatoid arthritis fails methotrexate, I

Add sulfasalazine and hydroxychloroquine (so-called triple therapy)
Add an anti-TNF
Add leflunomide (Arava)
Add abatacept (Orencia)
Add tocilizumab (Actemra)
Add JAK inhibitor tofacitinib (Xeljanz)
Add rituximab (Rituxan)
Related Videos
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.